Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$35.00MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sandesh C. Seth
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 27
- Beta
- 0.02
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -8.61
Financials
Revenue
$35.00M+5527.0%Net Income
$27.90MEBITDA
$28.14MFree Cash Flow
$-5.66MEPS (diluted)
$0.89Shares Outstanding (diluted)
31.41M+1877.8%Operating Expenses
$7.43MCash & Debt
$36.47MReturn of Capital
$0.00Revenue by Segment (annual)
$90.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $90.0K | $-33.89M | $-1.09 |
| 2024 | $0.00 | $-38.24M | $-1.27 |
| 2023 | $81.0K | $-48.82M | $-1.83 |
| 2022 | $1.03M | $-33.02M | $-1.37 |
| 2021 | $1.14M | $-24.77M | $-1.20 |
| 2020 | $0.00 | $-22.21M | $-1.83 |
| 2019 | $0.00 | $-21.90M | $-4.37 |
| 2018 | $0.00 | $-23.65M | $-6.69 |
| 2017 | $0.00 | $-26.60M | $-11.96 |
| 2016 | $0.00 | $-24.32M | $-15.06 |
| 2015 | $0.00 | $-21.02M | $-16.53 |
| 2014 | $0.00 | $-24.69M | $-27.07 |
| 2013 | $0.00 | $-10.77M | $-14.21 |
| 2012 | $0.00 | $-8.36M | $-227.31 |
Valuation
ATNMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+400.00%Social Signal Score
Mentions (4)
- Newsprnewswire.com·5h ago·Neutral
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal cancer data demonstrate ATNM-400's potential to enhance responses to standard-of-care therapies Ovarian cancer data demonstr…
View source ↗ - Newsprnewswire.com·6h ago·Neutral
…ng and strategic transactions across Actinium's targeted radiotherapy pipeline NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Sean Maenpaa as Senior Vice President, Business Development, effective October 12, 2026. Mr. Maenpaa will lead the Company's business development activities, including out-licensing, partnering and collabo…
View source ↗ - Newsprnewswire.com·1d ago·Neutral
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation of Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry to inform the development of Actinium-225-la…
View source ↗ - Newsprnewswire.com·62d ago·Negative
… Property and Manufacturing Advances and Provides NYSE American Listing Update NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quart…
View source ↗
Earnings
Fri, Nov 13(in 4 weeks)
Consensus estimate $-0.25 per share
Typical surprise +31.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$0.89 vs $-0.20beat
- Fri, May 8$-0.18 vs $-0.22beat
- Mon, Mar 30$-0.19 vs $-0.19miss
- Fri, Nov 14$-0.16 vs $-0.25beat
- Fri, Aug 8$-0.22 vs $-0.32beat
- Fri, May 9$-0.51 vs $-0.26miss
Estimates and results for ATNM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATNM officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ATNM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.